Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Follow-Up Questions
Scinai Immunotherapeutics Ltd (SCNI) 的市盈率是多少？
Scinai Immunotherapeutics Ltd 的市盈率是 0.2837
Scinai Immunotherapeutics Ltd 的 CEO 是谁？
Mr. Amir Reichman 是 Scinai Immunotherapeutics Ltd 的 Chief Executive Officer，自 2021 加入公司。
SCNI 股票的价格表现如何？
SCNI 的当前价格为 $1.55，在上个交易日 decreased 了 0.52%。
Scinai Immunotherapeutics Ltd 的主要业务主题或行业是什么？
Scinai Immunotherapeutics Ltd 属于 Biotechnology 行业，该板块是 Health Care
